Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma

Table 1 Correlation between HER-2 protein expression and HER-2 gene amplification

HER-2 FISH	Immunohistochemistry for HER-2				Total
	0 (n = 98)	1 (n = 25)	2 (n = 12)	3 (n = 10)
Negative	98	22	7	0	127
Positive	0	3	5	10	18

FISH: Fluorescence in situ hybridization.

Table 2 HER-2 protein expression and HER-2 gene amplification in gastric carcinoma tissue samples

Clinicopathologic data	n	HER-2 (IHC)		P value	HER-2 (FISH)		P value
		Pos	%		Amp	%
Sex
Male	95	14	14.7	NS	10	10.5	NS
Female	50	8	16.0		8	16.0
Age (yr)
> 60	68	10	14.7	NS	7	10.3	NS
≤ 60	77	12	15.6		11	14.3
Diameter of the tumor (cm)
> 5	85	15	17.6	NS	12	14.1	NS
≤ 5	60	7	11.7		6	10.0
Location
Cardia or fundus of stomach	55	8	14.5		7	12.7
Body of stomach	39	5	12.8	NS	4	10.3	NS
Sinus ventriculi/ostium pyloricum	51	9	17.6		7	13.7
Differentiation
Well	36	6	16.7		5	13.9
Moderately	44	5	11.4	NS	4	9.1	NS
Pooly/undifferentiated	65	11	16.9		9	13.8
Serosa invasion
Positive	107	20	18.7	< 0.05	17	15.9	< 0.05
Negative	38	2	5.3		1	2.7
Lymph node metastasis
Positive	91	20	22.0	< 0.05	18	19.8	< 0.05
Negative	54	2	3.7		0	0.0
Distant metastasis
Positive	11	10	90.9	< 0.05	9	81.8	< 0.05
Negative	134	12	9.0		8	6.0
TNM stage
I + II	67	3	4.5	< 0.05	2	2.99	< 0.05
III + IV	78	19	24.4		16	20.5
Histopathological classification(Lauren)
Intestinal	86	19	22.1		17	19.8
Diffuse	37	2	5.4	< 0.05	0	0.0	< 0.05
Non classified	22	1	4.5		1	4.5

IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization; NS: Not significant.